Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters

@article{Gidal2017EffectOE,
  title={Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters},
  author={B E Gidal and Rama Maganti and Antonio Laurenza and Haichen Yang and David Verbel and Edgar Schuck and Jim Ferry},
  journal={Epilepsy Research},
  year={2017},
  volume={134},
  pages={41-48}
}
OBJECTIVES Perampanel, a selective, noncompetitive AMPA receptor antagonist, is indicated as adjunctive therapy for the treatment of partial seizures with or without secondarily generalized seizures and primary generalized tonic-clonic seizures in patients with epilepsy aged 12years and older. In vitro studies and Phase I trials indicate that perampanel is… CONTINUE READING